Cargando…

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

The current coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus genetically close to SARS-CoV. To investigate the effects of previous SARS-CoV infection on the ability to recognize and neutralize SARS-CoV-2, we a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yuanmei, Yu, Danwei, Han, Yang, Yan, Hongxia, Chong, Huihui, Ren, Lili, Wang, Jianwei, Li, Taisheng, He, Yuxian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673700/ https://www.ncbi.nlm.nih.gov/pubmed/33036961 http://dx.doi.org/10.1126/sciadv.abc9999

Ejemplares similares

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
por: Cao, Zhiliang, et al.
Publicado: (2010)

Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor
por: Sun, Youxiang, et al.
Publicado: (2017)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Long-Term Persistence of Robust Antibody and Cytotoxic T Cell Responses in Recovered Patients Infected with SARS Coronavirus
por: Li, Taisheng, et al.
Publicado: (2006)

Immunogenicity of SARS-CoV: the Receptor-Binding Domain of S Protein is a Major Target of Neutralizing Antibodies
por: He, Yuxian
Publicado: (2006)

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
por: Geng, Xiuzhu, et al.
Publicado: (2019)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
por: Yu, Danwei, et al.
Publicado: (2020)

Assessment of Antibody and T-Cell Responses to the SARS-CoV-2 Virus and Omicron Variant in Unvaccinated Individuals Recovered From COVID-19 Infection in Wuhan, China
por: Guo, Li, et al.
Publicado: (2022)

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
por: Chi, Xiaojing, et al.
Publicado: (2020)

Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19
por: Kim, Yoon-Jung, et al.
Publicado: (2021)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins
por: Tripp, Ralph A., et al.
Publicado: (2005)

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients
por: Luchsinger, Larry L., et al.
Publicado: (2020)

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients
por: Luchsinger, Larry L., et al.
Publicado: (2020)

One‐year persistence of neutralizing anti‐SARS‐CoV‐2 antibodies in dialysis patients recovered from COVID‐19
por: Alfano, Gaetano, et al.
Publicado: (2021)

Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy
por: Jin, Hongliang, et al.
Publicado: (2021)

Profiling of SARS‐CoV‐2 neutralizing antibody‐associated antigenic peptides signature using proteome microarray
por: Wu, Mingkun, et al.
Publicado: (2023)

Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
por: Takeshita, Masaru, et al.
Publicado: (2022)

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
por: Wu, Nicholas C., et al.
Publicado: (2020)

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody
por: Wu, Nicholas C., et al.
Publicado: (2020)

Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19
por: Liu, Wang-Da, et al.
Publicado: (2022)

Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2
por: Ahn, Terrie S., et al.
Publicado: (2021)

Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay
por: Zhang, Hui, et al.
Publicado: (2022)

Neutralizing Antibody Response and SARS Severity
por: Ho, Mei-Shang, et al.
Publicado: (2005)

Effect of COVID-19 Vaccination on the Levels of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Naive, Hybrid, and Breakthrough SARS-CoV-2 Recovered Indian Individuals
por: Deepika, Gujjarlapudi, et al.
Publicado: (2023)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
por: Liu, Mingtao, et al.
Publicado: (2023)

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
por: Liu, Zhuoming, et al.
Publicado: (2021)

Antibody-mediated neutralization of SARS-CoV-2
por: Gruell, Henning, et al.
Publicado: (2022)

Neutralizing antibodies for SARS-CoV-2 infection
por: Berenguer, Juan
Publicado: (2022)

Neutralizing antibodies for SARS-CoV-2 in stray animals from Rio de Janeiro, Brazil
por: Dias, Helver Gonçalves, et al.
Publicado: (2021)

Development of a rapid neutralizing antibody test for SARS-CoV-2 and its application for neutralizing antibody screening and vaccinated serum testing
por: Li, Yuchang, et al.
Publicado: (2022)

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities
por: Qiu, Maofeng, et al.
Publicado: (2005)

Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses
por: Bullen, Georgia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tbfssm71ppne85fh39j0crir4o